Adverse reactions observed in the phase III MOVe-OUT study included diarrhea (2%), nausea (1%) and dizziness (1%), all of which were mild or moderate.
Molnupiravir
Balapiravir
Odalasvir
Saquinavir
Remdesivir
Coronavir
Favipiravir
Maribavir